Clik here to view.
Clik here to view.
Mary Kay在Regeneron国际科学与工程博览会上为五名年轻有为的科学家颁发资助金
达拉斯 (美国商业资讯)– Mary Kay Inc.,积极支持STEM教育和青少年追逐梦想。该公司最近在洛杉矶举行的 Regeneron国际科学与工程博览会（ISEF）上，向从代表近70个国家的近2000名参赛者中选出的五名优秀高中科学家颁发了三个资助奖。这些资助总额近1万美元，颁发给了那些专注于寻找女性癌症治疗方法、可持续包装创新和保护地球最宝贵资源的创新项目的学生。...
View ArticleClik here to view.
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for...
SAN MATEO, Calif. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American...
View ArticleClik here to view.
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival...
TOKYO & BASKING RIDGE, N.J. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS),...
View ArticleClik here to view.
AIを活用した抗がん剤と再生医療で革新的な新薬の開発で、OncocrossがJWファーマシュティカルとの提携を拡大
韓国・ソウル （ビジネスワイヤ） — ソウルに拠点を置くAI創薬・開発バイオテクノロジー企業であるOncocrossは5月22日、AIプラットフォームに基づく新薬開発のため、JWファーマシュティカルと共同研究契約を締結したと発表しました。...
View ArticleClik here to view.
Oncocross Expands Collaboration with JW Pharmaceutical on Developing...
SEOUL, South Korea Oncocross, a Seoul-based AI drug discovery and development biotech, announced on May 22nd that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs...
View ArticleClik here to view.
TVMキャピタル・ヘルスケア、 サウジアラビア特化の「TVMヘルスケア・アフィア・ファンド」のクロージングを発表
サウジアラビア・リヤド＆アラブ首長国連邦・ドバイ （ビジネスワイヤ） — ヘルスケア分野の事業拡大・成長資金の国際投資企業であるTVMキャピタル・ヘルスケアは、中東における2番目の資本プールとなる「TVMヘルスケア・アフィア・ファンドLP」の約2億5,000万米ドルでのクロージングを発表しました。...
View ArticleClik here to view.
TVM Capital Healthcare宣布聚焦沙特阿拉伯的TVM Healthcare Afiyah Fund结束募资
沙特阿拉伯利雅得和阿联酋迪拜 (美国商业资讯)– 国际医疗保健扩张和成长资本投资公司TVM Capital Healthcare今天宣布完成约2.5亿美元的TVM Healthcare Afiyah Fund LP募资，这是该公司在中东地区的第二个资金池。 TVM Capital...
View ArticleClik here to view.
BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy...
MIAMI Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary endpoint of...
View ArticleClik here to view.
Clik here to view.
Parse Biosciences推出Trailmaker数据分析平台以简化单细胞测序
西雅图 (美国商业资讯)– Parse Biosciences是领先的易访问和可扩展单细胞测序解决方案提供商，今天宣布该公司专为单细胞数据分析而构建的用户友好型云平台Trailmaker™正式上线。Trailmaker具有快速、可扩展的特点，可提供端到端的分析，消除了常见的分析壁垒，可快速将单细胞数据转换为生物学见解。...
View ArticleClik here to view.
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for...
MIAMI Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing...
View ArticleClik here to view.
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial...
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the...
View ArticleClik here to view.
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients...
CRANBURY, N.J. Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy...
View ArticleClik here to view.
Accutar Biotechnology在2024年ASCO年会上公布了在ER+/HER2-乳腺癌患者中开展AC699单一疗法一期试验的数据
新泽西州克兰伯里 (美国商业资讯)– Accutar Biotechnology,...
View ArticleClik here to view.
Accutar Biotechnology、ASCO 2024にてER +/ HER2-乳がん患者におけるAC699単剤療法の第1相試験データを発表
クランベリー、ニュージャージー州 （ビジネスワイヤ） — 人工知能（AI）対応創薬に焦点を当てたバイオテクノロジー企業のAccutar Biotechnology,...
View ArticleClik here to view.
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR...
TOKYO & BASKING RIDGE, N.J. Detailed positive results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and...
View ArticleClik here to view.
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
MIAMI Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company received and accepted an unsolicited offer from an institutional investor to...
View ArticleClik here to view.
Inocras and Massive Bio Forge Groundbreaking Alliance to Revolutionize Cancer...
SAN DIEGO Inocras, a leading AI-driven whole genome testing company, and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a new standard for...
View Article